Opinion

Stephen V Liu: Cataloging Success – Repotrectinib’s Efficacy in a ROS1 NSCLC Resistance Case

Stephen V Liu/X

Aug 13, 2025, 20:22

Stephen V Liu: Cataloging Success – Repotrectinib’s Efficacy in a ROS1 NSCLC Resistance Case

Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Yukiko Yoshida et al. published in Clinical Lung Cancer:

“Case report of efficacy with repotrectinib in ROS1 NSCLC with the solvent front D2033N resistance mutation. Good to catalog but less relevant as newer ROS1 agents become standard first-line therapy.”

Title: First clinical evidence of repotrectinib efficacy in ROS1-rearranged NSCLC with a D2033N resistance mutation: case report

Authors: Yukiko Yoshida, Hiroshi Yokouchi, Hidenori Mizugaki, Noriyuki Yamada, Hajime Asahina, Hitoki Inoue, Masaharu Nishimura, Satoshi Oizumi

You can read the Full Article on Clinical Lung Cancer.

Stephen V Liu: Cataloging Success - Repotrectinib's Efficacy in a ROS1 NSCLC Resistance Case

More posts featuring Stephen V Liu.

cancer Clinical Lung Cancer Hajime Asahina Hidenori Mizugaki Hiroshi Yokouchi Hitoki Inoue Lung cancer Masaharu Nishimura Noriyuki Yamada NSCLC OncoDaily Oncology Repotrectinib Satoshi Oizumi Stephen V Liu Yukiko Yoshida

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders